Xu Jing Su
Investor Relations Contact chez Taizhou EOC Pharma Co., Ltd.
Profil
Xu Jing Su currently works at Taizhou EOC Pharma Co., Ltd., as Board Secretary & Legal Director from 2019.
Mr. Su received his graduate degree in 2009 from Soochow University and graduate degree in 2005 from Yanshan University.
Postes actifs de Xu Jing Su
Sociétés | Poste | Début |
---|---|---|
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | Investor Relations Contact | - |
Formation de Xu Jing Su
Yanshan University | Graduate Degree |
Soochow University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | Health Technology |